Results 191 to 200 of about 12,784,255 (313)

Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy

open access: yesFEBS Letters, EarlyView.
The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley   +1 more source

The oral-gut microbiota relationship in healthy humans: identifying shared bacteria between environments and age groups

open access: yesFrontiers in Microbiology
IntroductionAlthough the oral cavity and the gut are anatomically continuous regions of the gastrointestinal tract, research on the relationship between oral and gut microbiota remains sparse.
Carolina F. F. A. Costa   +10 more
doaj   +1 more source

Unlocking the potential of cell‐permeable nanobodies for intracellular applications

open access: yesFEBS Letters, EarlyView.
This review outlines current strategies for delivery of nanobodies into cells and highlights recent examples of functional applications. By addressing and manipulating intracellular targets, these molecules hold great potential for treating cancer, respiratory diseases and neurological disorders, making this a vibrant area of research in the biomedical
Mariona Gené‐Verdés   +2 more
wiley   +1 more source

How structural disorder and polyelectrolyte properties of prothymosin α enable its large interactome

open access: yesFEBS Letters, EarlyView.
In this review, complexes of the fully disordered and highly negatively charged prothymosin α are collected, described, and discussed. Linked to its poly‐electrostatic character, prothymosin α engages a large interactome through multiple different binding modes ranging from fully disordered complexes to short linear motif (SLiM)‐driven interactions ...
Ketty C. Tamburrini   +3 more
wiley   +1 more source

Advances in targeted therapy [PDF]

open access: yesRheumatology, 2016
Breedveld, F.C.   +2 more
openaire   +3 more sources

Mitochondrial translation and coordinated cytosolic translation in metabolic homeostasis and disease

open access: yesFEBS Letters, EarlyView.
Mitochondrial function depends on coordinated protein production from the nuclear and mitochondrial genomes. This review highlights how cytosolic and mitochondrial translation, mRNA localization, protein import, and respiratory complex assembly are integrated to maintain mitochondrial proteostasis and function.
Boseon Kim   +4 more
wiley   +1 more source

Dynamic biomarkers in hormone receptor-positive/HER2-negative breast cancer trials: a new hope for precision oncology

open access: yesnpj Breast Cancer
Hormone receptor-positive/HER2-negative breast cancer evolves in response to therapy, demanding smarter, adaptive biomarker-based treatment strategies. We review emerging dynamic biomarkers to guide therapeutic decision-making, spanning tissue and liquid
Giuseppe Di Grazia   +10 more
doaj   +1 more source

Targeted cancer therapies Oral health care implications

open access: yes, 2018
Background. Targeted treatments have been incorporated into oncology protocols, often with more traditional therapies, and are not totally free of adverse reactions, some of which affect the orofacial region. Methods.
Georgakopoulou, Eleni   +2 more
core   +1 more source

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

open access: yesMolecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Approaches to interpret the outcomes of a network meta-analysis on comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following progression on prior endocrine therapy

open access: yes, 2019
Rama Jayaraj,1 Chellan Kumarasamy,2 Shanthi Sabarimurugan,3 Suja Samiappan41College of Health and Human Sciences, Charles Darwin University, Casuarina, Northern Territory 0909, Australia; 2University of Adelaide, Adelaide, South Australia 5005, Australia;
Kumarasamy C   +3 more
core  

Home - About - Disclaimer - Privacy